Key facts
- This page summarizes Michael Cordonnier's Form 3 filing for CARLSMED, INC..
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 22 Jul 2025, 17:31.
Michael Cordonnier - 22 Jul 2025 Form 3 Insider Report for CARLSMED, INC.
- Reporting relationship
- CEO, President, Director
- Issuer ticker
- CARL on Nasdaq
- Reported as of
- 22 Jul 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 22 Jul 2025, 17:31:25 UTC
- Next SEC filing
- 30 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Cordonnier
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Cordonnier filed Form 3 for CARLSMED, INC. on 22 Jul 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002077087
Primary reporting owner
Cordonnier Michael
- Relationship
- CEO, President, Director
- Address
- C/O CARLSMED, INC., 1800 ASTON AVE., SUITE 100, CARLSBAD
- Signature
- /s/ Michael Cordonnier
- Signature date
- 22 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARL
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,235,718
- Date
- 22 Jul 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CARL
holding
Derivative
Series B Preferred Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,612
- Exercise price
- Footnotes
- F2
CARL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 358,422
- Exercise price
- $0.3300
- Footnotes
- F3, F5
CARL
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 224,956
- Exercise price
- $4.35
- Footnotes
- F4, F5
CARL
holding
Derivative
Restricted Stock Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Jul 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 112,478
- Exercise price
- Footnotes
- F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
These shares of common stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split").
Footnote F2
Includes 3,612 shares of Series B Preferred Stock issued to the Reporting Person on April 18, 2022. Each share of Series B Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported after giving effect to the Reverse Split and on an as-converted 1-to-1 basis and have no expiration date.
Footnote F3
Includes 358,422 vested stock options convertible into approximately 358,422 shares of the Issuer's common stock. These options are reported after giving effect to the Reverse Split and became fully vested on December 15, 2024.
Footnote F4
Includes 224,956 unvested stock options convertible into approximately 224,956 shares of the Issuer's common stock which began to vest on December 15, 2024, subject to a one-year cliff, and will be fully vested on December 15, 2028. These options are reported after giving effect to the Reverse Split.
Footnote F5
The exercise price has been adjusted to reflect the Reverse Split.
Footnote F6
Includes 112,478 unvested restricted stock units convertible into approximately 112,478 shares of the Issuer's common stock that are subject to milestone and performance-based vesting. These restricted stock units are reported after giving effect to the Reverse Split.